

Kelso Pharma Appoints Life Sciences Executive, Gordon Cameron, as Chairman

London, UK – 6th July, 2022. Apposite-backed Kelso Pharma, the growing specialty pharma business, has appointed senior Life Sciences executive Gordon Cameron OBE, as its Non-Executive Chairman.

A senior executive with 25 years' Board-level experience in private equity and plc listed businesses, Gordon has worked in the UK and US, primarily in biotech and pharmaceutical services. Originally with Ernst & Young, Gordon had several years in investment banking with Rothschild before becoming CFO and then CEO of FTSE-250 international vaccines company, Acambis plc. Gordon has spent the last 15 years as CFO with Quotient Sciences, a private-equity backed international CDMO and CRO. During his time there, revenues grew 15-fold and Gordon has led it through four changes of private equity ownership. In 2004, Gordon was awarded the Officer of the Order of the British Empire for services to the British biotechnology industry in the US.

Kelso Pharma aims to bring innovative, value added, specialty medicines to the European healthcare markets, providing medicines that improve the lives of patients in a cost-effective and ethical manner. Kelso Pharma is growing through a blend of company & product acquisitions, partnerships, and organic growth, both in the UK and in Europe.

Commenting on the appointment, Kelso Pharma CEO, Dr. Tom Stratford, said: "We're thrilled to welcome Gordon to the Kelso Pharma team as our Chairman. He brings extensive industry experience, as well as a deep understanding of growing businesses under private equity ownership. Gordon's experience, skillset and knowledge demonstrate the calibre of people we're looking to work with at Kelso Pharma. We aim to provide medicines that improve the lives of patients on a daily basis, and we look forward to working with Gordon as we continue to grow the business."

Gordon Cameron added: "I'm very excited to be joining Kelso Pharma at a busy and pivotal time for the business as they look to grow, both organically and by acquisition. With the aim of providing value-added medicines to the market in an ethical manner with people at the heart of decision making aligns with my own values and I'm looking forward to playing a part in driving Kelso Pharma's growth."

Sam Gray, Managing Partner of Apposite Capital, also commented: "Gordon is a seasoned industry executive whose extensive experience in growing businesses organically and through acquisition over multiple rounds of PE ownership perfectly complements the stellar track record of the Kelso team in building and growing specialty pharma businesses of scale. We are delighted to welcome him to the team."



Kelso Pharma CEO Dr Tom Stratford and Non-Executive Chairman Gordon Cameron

– end –

Media contact:

Victoria O’Gorman

Tel: +44(0) 20 3475 1710

Email: victoria.ogorman@appositecapital.com

About Apposite Capital

www.appositecapital.com

Apposite Capital is an independent investment firm focused exclusively on healthcare. It backs companies operating in health and social care, medtech & medical products, pharmaceuticals & life sciences and digital health.

Apposite Capital operates at the small end of the private equity market, providing both capital and expertise to those businesses offering ‘disruptive’ models that aim to improve or reduce the cost of care provision and which have the potential to become market leaders.

Apposite has an in-depth sector knowledge covering key aspects of the healthcare industry internationally, an exceptional network and an entrepreneurial mindset which it applies to drive the growth of its portfolio companies both organically and inorganically.

Apposite Capital was established in 2006 and is headquartered in London, UK.

About Kelso Pharma

www.kelsopharma.com

Kelso Pharma is committed to bringing innovative, value-added, specialty medicines to the European healthcare markets, that provide meaningful benefits to patients and create added value for healthcare stakeholders. Kelso Pharma is headed by Dr Tom Stratford, previously CEO of Kyowa Kirin International (“KKI”), the European and US business arm of Kyowa Kirin, which purchased Scottish Borders based ProStrakan Group PLC in 2011. He is joined in this new venture by former KKI CFO, Allan Watson, and former KKI General Counsel, Andrew McLean.

Dr Tom Stratford, CEO

With a PhD in developmental biology, Tom Stratford is an experienced CEO, with over 25 years in the pharma sector, building commercial pharma organisations in the EMEA and USA. Highly experienced in developing businesses through organic growth and M&A, Tom was the founding member of the ProStrakan business development team, leading the team for 15 years. As CEO of KKI, he led the EMEA business from turnover of £100m with significant growth in revenues and expansion across Europe.

Allan Watson, CFO

Chief Financial Officer with over 25 years of finance experience including ILC Therapeutics, KKI and Optos plc. Extensive international and M&A experience. A pharmacy graduate, he has held a number of finance positions with small and large companies both within and outside of the healthcare sector since qualifying as an accountant.

Andrew McLean, General Counsel

General Counsel with over 25 years’ pharma sector experience at Camurus AB, KKI, Recordati and Shire. Extensive M&A, corporate finance, business development, licensing, IP management and litigation, compliance, private and listed company experience.